JPH0717517B2 - 新規化合物、その製法及びそれを含む医薬組成物 - Google Patents

新規化合物、その製法及びそれを含む医薬組成物

Info

Publication number
JPH0717517B2
JPH0717517B2 JP60269206A JP26920685A JPH0717517B2 JP H0717517 B2 JPH0717517 B2 JP H0717517B2 JP 60269206 A JP60269206 A JP 60269206A JP 26920685 A JP26920685 A JP 26920685A JP H0717517 B2 JPH0717517 B2 JP H0717517B2
Authority
JP
Japan
Prior art keywords
group
formula
conjugate
protein
pharmaceutically useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP60269206A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61155333A (ja
Inventor
アンドルー・ジヨン・ガーマン
Original Assignee
ビーチャム・グループ・ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10570497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0717517(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ビーチャム・グループ・ピーエルシー filed Critical ビーチャム・グループ・ピーエルシー
Publication of JPS61155333A publication Critical patent/JPS61155333A/ja
Publication of JPH0717517B2 publication Critical patent/JPH0717517B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP60269206A 1984-11-30 1985-11-29 新規化合物、その製法及びそれを含む医薬組成物 Expired - Fee Related JPH0717517B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8430252 1984-11-30
GB848430252A GB8430252D0 (en) 1984-11-30 1984-11-30 Compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP6023584A Division JP2545339B2 (ja) 1984-11-30 1994-01-27 水溶性重合体含有試薬

Publications (2)

Publication Number Publication Date
JPS61155333A JPS61155333A (ja) 1986-07-15
JPH0717517B2 true JPH0717517B2 (ja) 1995-03-01

Family

ID=10570497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP60269206A Expired - Fee Related JPH0717517B2 (ja) 1984-11-30 1985-11-29 新規化合物、その製法及びそれを含む医薬組成物
JP6023584A Expired - Fee Related JP2545339B2 (ja) 1984-11-30 1994-01-27 水溶性重合体含有試薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP6023584A Expired - Fee Related JP2545339B2 (ja) 1984-11-30 1994-01-27 水溶性重合体含有試薬

Country Status (9)

Country Link
US (1) US4935465A (https=)
EP (1) EP0183503B1 (https=)
JP (2) JPH0717517B2 (https=)
AU (1) AU5044585A (https=)
DE (1) DE3586313T2 (https=)
DK (1) DK552285A (https=)
GB (1) GB8430252D0 (https=)
GR (1) GR852877B (https=)
PT (1) PT81581B (https=)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4842868A (en) * 1986-09-26 1989-06-27 Helwing Robert F Covalently bonded active agents with carbonium ion base groups
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
AU611932B2 (en) * 1987-08-21 1991-06-27 Wellcome Foundation Limited, The Novel complex
JPH079429B2 (ja) * 1988-10-12 1995-02-01 財団法人化学及血清療法研究所 人工担体およびその製造方法
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
FI901810A7 (fi) * 1989-04-13 1990-10-14 Vascular Laboratory Inc Puhtaan pro-urokinaasin plasminogeeniaktivaattorikompleksi, joka on sidottu ihmisen seerumialbumiiniin disulfidisillan välityksellä
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
US5767072A (en) * 1989-09-14 1998-06-16 Board Of Regents, The University Of Texas System Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU5610194A (en) 1992-11-16 1994-06-08 Centocor Inc. Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds
DK0675727T3 (da) * 1992-12-10 2002-08-05 Enzon Inc Glycolipidenzympolymerkonjugater
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
ATE214940T1 (de) * 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
WO1996004340A1 (en) * 1994-08-04 1996-02-15 Gordon George Wallace Conducting electroactive biomaterials
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
FI972443A7 (fi) * 1994-12-07 1997-06-09 Novozymes As Polypeptidi, jonka allergeenisuus on vähentynyt
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6428790B1 (en) * 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
WO1997022371A1 (en) * 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
WO1997024421A2 (en) * 1995-12-29 1997-07-10 The Procter & Gamble Company Detergent compositions comprising immobilized enzymes
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
CN1273589C (zh) * 1996-02-15 2006-09-06 诺沃奇梅兹有限公司 多肽缀合
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
JPH10276776A (ja) * 1997-04-07 1998-10-20 Toyobo Co Ltd 可逆的に不活化された耐熱性ｄｎａポリメラーゼ
US6214594B1 (en) 1998-05-08 2001-04-10 University Of California Size enhanced fibrinolytic enzymes: limitations of plasma inactivation
DK1087778T3 (da) * 1998-06-08 2005-12-19 Hoffmann La Roche Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
TWI242000B (en) * 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
ATE340592T1 (de) * 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
EP1198565A1 (en) * 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
US6423666B1 (en) 1999-10-05 2002-07-23 Bio-Rad Laboratories, Inc. Large-pore chromatographic beads prepared by suspension polymerization
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
KR100773323B1 (ko) 2000-01-10 2007-11-05 맥시겐 홀딩스 리미티드 지-씨에스에프 접합체
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7829074B2 (en) * 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
GB0123232D0 (en) * 2001-09-26 2001-11-21 Smith & Nephew Polymers
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
UA86744C2 (en) 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2003303513A1 (en) * 2002-12-30 2004-07-29 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
GB0305989D0 (en) * 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2005105154A1 (en) * 2004-04-21 2005-11-10 Alza Corporation Polymer conjugate releasable under mild thiolytic conditions
CN104174071A (zh) 2004-04-28 2014-12-03 安希奥设备国际有限责任公司 用于形成交联生物材料的组合物和系统及关联的制备方法与用途
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1796602A4 (en) 2004-09-17 2016-10-19 Angiotech Pharm Inc MULTIFUNCTIONAL COMPOUNDS FOR PRODUCING NETWORKED BIOMATERIALS AND MANUFACTURING AND USE METHOD THEREFOR
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
DK2339014T3 (en) 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
WO2008057298A2 (en) 2006-10-27 2008-05-15 Wei-Chiang Shen Lipidized interferon and uses thereof
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
EP2195333A1 (en) * 2007-09-12 2010-06-16 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
US8440787B2 (en) * 2007-10-23 2013-05-14 Nektar Therapeutics Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
US20110027267A1 (en) * 2007-11-09 2011-02-03 Anaphore, Inc. Fusion Proteins of Mannose Binding Lectins for Treatment of Disease
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US20110318322A1 (en) * 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
GB201117428D0 (en) * 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019243523A1 (en) 2018-06-21 2019-12-26 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
CA3111576A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
BR112021020226A2 (pt) 2019-04-10 2021-12-07 Cellestia Biotech Ag Inibidores de via de sinalização notch e uso dos mesmos no tratamento de cânceres
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021242249A1 (en) 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
WO2022122667A1 (en) 2020-12-07 2022-06-16 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
CN112451681B (zh) * 2020-12-09 2023-08-25 苏州大学 酸敏感型聚合物-药物偶联物及其制备和应用
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
EP4429661A1 (en) 2021-11-08 2024-09-18 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH453709A (de) * 1964-12-05 1968-03-31 Cassella Farbwerke Mainkur Ag Verfahren zur Anlagerung von Maleinsäureanhydrid an Polyalkylenäther
GB1390716A (en) * 1972-06-27 1975-04-16 Mitsubishi Electric Corp Ester of trimellitic anhydride and process for producing the same
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0038154B1 (en) * 1980-04-15 1983-09-21 Beecham Group Plc Allergens modified with polysarcosines
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58225025A (ja) * 1982-06-24 1983-12-27 Nippon Chem Res Kk 効力持続性組成物
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4859736A (en) * 1987-03-30 1989-08-22 Ciba-Geigy Corporation Synthetic polystyrene resin and its use in solid phase peptide synthesis

Also Published As

Publication number Publication date
GR852877B (https=) 1986-03-31
EP0183503A2 (en) 1986-06-04
GB8430252D0 (en) 1985-01-09
PT81581A (en) 1985-12-01
DK552285A (da) 1986-05-31
AU5044585A (en) 1986-07-17
EP0183503B1 (en) 1992-07-08
JPS61155333A (ja) 1986-07-15
JPH06279318A (ja) 1994-10-04
DE3586313D1 (de) 1992-08-13
EP0183503A3 (en) 1988-01-07
JP2545339B2 (ja) 1996-10-16
PT81581B (en) 1987-07-22
US4935465A (en) 1990-06-19
DE3586313T2 (de) 1993-01-21
DK552285D0 (da) 1985-11-28

Similar Documents

Publication Publication Date Title
JP2545339B2 (ja) 水溶性重合体含有試薬
US4673573A (en) Novel fibrinolytic enzyme compounds
CA2500389C (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US4808405A (en) P-anisoyl streptokinase/plasminogen complex
US4908204A (en) Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and pharmaceutical compositions and anti-thrombotic use thereof
US8129330B2 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
DE69015182T2 (de) Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.
US4970159A (en) Human tissue plasminogen activator consisting essentially of t-PA residues 160 to 527
EP0283563B1 (en) Novel derivatives
Bode et al. Thrombolysis by a fibrin-specific antibody Fab′-urokinase conjugate
JPH0567278B2 (https=)
US7157458B2 (en) Bifunctional energy-reversible acyl-compositions
JPH01240186A (ja) フィブリン特異性２本鎖プラスミノーゲンアクチベーター
EP0181596B1 (en) Process for preparing a urokinase complex
JPS63269980A (ja) 新規化合物、その製法及びそれを含む医薬組成物
US5234686A (en) Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
JP2002514411A (ja) サイズ拡大型繊維素溶解酵素、及び繊維素溶解酵素のサイズ変更方法
JPH0327286A (ja) 組織プラスミノーゲン活性化因子の誘導体
ZA200502707B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO1999009185A1 (de) Plasminogenaktivator mit verbesserter zymogenität
HK1083190B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JPS62108824A (ja) 新規なウロキナ−ゼ重合体及び該重合体を有効成分とする血栓溶解剤

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees